COMMUNIQUÉS West-GlobeNewswire

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
15/07/2026
LA JOLLA, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
15/07/2026
Patients with restrictive lung disease demonstrate clinically meaningful benefit in FVC and improvements in multiple PROs for 5.0 mg/kg efzofitimod compared to placebo. Company submitted protocol to FDA in June 2026 for [...]
InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
15/07/2026
BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational [...]
Cardiff Oncology Announces $10 Million Registered Direct Offering
15/07/2026
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced [...]
Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
15/07/2026
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today announced that it will [...]
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
15/07/2026
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple Myeloma Publication Supports Continued Development of Iopofosine I 131 as a Novel Targeted Radiotherapeutic Across [...]
Glass House Brands Announces the Filing of an Updated At-The-Market Distribution Program
15/07/2026
LONG BEACH, Calif. and TORONTO, July 15, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (NYSE: GLAS) today announced that it has updated its at-the-market [...]
Sienna Announces July Dividend
15/07/2026
MARKHAM, Ontario, July 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
15/07/2026
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety [...]
Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn
15/07/2026
RALEIGH, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- Slate Medicines (Slate), a privately-held biotech company advancing next-generation therapeutics for migraine and other headache disorders, today announced the [...]
Attovia Therapeutics Appoints John W. Smither to Board of Directors
15/07/2026
Mr. Smither brings extensive public company board and audit committee experience in the biotechnology sector SAN CARLOS, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company [...]
Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
15/07/2026
- The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which the Banner MD Anderson [...]
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
15/07/2026
RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102 No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild and consistent with [...]
Mixie Technologies, Inc. (OTC: MIXE) Completes Corporate Rebranding and Trading Symbol Change
15/07/2026
Mixie Technologies focuses on acquiring companies and intellectual property built on unique, application-focused technology designed to deliver an advantage to customers, then scales them with AI-driven engineering [...]
Persephoni Backs SelSym Biotech to Bring Blood-Type-Agnostic Bleeding Control to the Point of Injury
15/07/2026
SelSym Biotech joins Persephoni to advance the first shelf-stable, blood-type agnostic hemostatic therapy designed for use at the point of injury, where no such option exists today RESEARCH TRIANGLE PARK, N.C., July 15 [...]
Cannara annonce un chiffre d’affaires record au troisième trimestre et une rentabilité soutenue, parallèlement à l’extension de sa distribution nationale et à l’accélération de l’augmentation de ses capacités
15/07/2026
De solides résultats financiers au troisième trimestre : 31,8 millions de dollars en produits totaux, déduction faite des taxes d’accise, une marge brute avant ajustements de la juste valeur de 13,4 millions de dollars [...]
Epoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approach
15/07/2026
7C11 antibody builds on APOE Christchurch variant biology associated with resilience to Alzheimer’s disease, including effects on tau, amyloid and the brain vasculature New non-human primate data demonstrate favorable [...]
Nxera Pharma Webinar for Financial Results Presentation - 2Q2026
15/07/2026
Tokyo, Japan and Cambridge and London, UK, 15 July 2026 – Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings results and present operational highlights for 2Q 2026 on Friday, 7 August 2026. The Company [...]
WONDERLAB Spotlights Gut Health and Innate Immunity, Featuring Its Proprietary Strain GOLDGUT-M520
15/07/2026
SHENZHEN, China, July 15, 2026 (GLOBE NEWSWIRE) -- On May 21, 2026, WONDERLAB ran a public science-education series on gut health and immunity, featuring its proprietary strain GOLDGUT-M520. The program included an [...]

Pages